Clinical data | |
---|---|
Trade names | Lyfnua |
Other names | MK-7264 |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
ECHA InfoCard | 100.258.106 |
Chemical and physical data | |
Formula | C14H19N5O4S |
Molar mass | 353.40 g·mol−1 |
3D model ( JSmol) | |
| |
|
Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough. [1] It acts as an antagonist of the P2RX3 receptor. [2] [3] [4]
It was approved for medical use in the European Union in September 2023. [1]
Gefapixant is indicated for the treatment of refractory or unexplained chronic cough. [1]
It was named in honour of Geoff Burnstock. [5]
Clinical data | |
---|---|
Trade names | Lyfnua |
Other names | MK-7264 |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
ECHA InfoCard | 100.258.106 |
Chemical and physical data | |
Formula | C14H19N5O4S |
Molar mass | 353.40 g·mol−1 |
3D model ( JSmol) | |
| |
|
Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough. [1] It acts as an antagonist of the P2RX3 receptor. [2] [3] [4]
It was approved for medical use in the European Union in September 2023. [1]
Gefapixant is indicated for the treatment of refractory or unexplained chronic cough. [1]
It was named in honour of Geoff Burnstock. [5]